Getting Single-Cell RNA-Seq Right Starts Before You Sequence

Single-cell methods allow researchers to resolve cellular heterogeneity within tissues, rather than make biological conclusions based on the average state of their tested population. As single-cell RNA sequencing (scRNA-seq) gains popularity, its protocols are rapidly evolving, with scientists having to consider various techniques with differences in methods, cell number, sequencing depth, sensitivity, cost, and time.¹ There are several key decisions along that path, including experimental design, sample preparation, capture method, sequencing depth, and controls.

With so many choices to make, a researcher must start with a solid plan that will ultimately best address their biological question. “One of the most common mistakes is treating single-cell sequencing as a workflow decision rather than an experimental design decision,” says Aisling Sinclair, Senior Product Marketing Manager at Parse Biosciences. “Researchers should clearly define their scientific question by understanding their biological comparisons, the populations they need to resolve, and the variability they need to capture ahead of establishing a target cell number or platform.”

Without these considerations, scientists could end up with data that show differences due to sample processing or that lack the statistical power to fully answer their question. Furthermore, deviating from the best experimental design for the question at hand due to external constraints could be more costly in the end. “The most expensive mistakes in single-cell design aren’t made at the bench—they’re made when researchers underpower their experimental design based on budget instead of biology,” says Jason Bell, Director of Business Development at Ultima Genomics.

One major early decision point is whether the question calls for unbiased discovery or a focused quantification of a gene panel. Making this choice at the outset will set you up for success down the line. “Reverse transcription-based whole transcriptome capture measures beyond a predefined gene list and can be a strong fit for discovery, unexpected cell states, noncoding RNA, or transcript level variation. Probe-based approaches may suit studies with well-defined targets, but probe design, binding efficiency, and the number of probes bound to each gene can influence the resulting counts,” notes Sinclair.

Sample preparation

“Sample preparation is the most important driver of whether or not your experiment will yield good data, so it is worth spending time on,” says Sinclair. “Researchers should look for others working with the same tissue or species, ask what has worked, and start with protocols supported by that experience rather than developing a method in isolation.”

A researcher’s sample type often drives decisions for sample prep and beyond. scRNA-seq can be performed on a variety of starting material, from 2D cell culture and organoids to blood and tissue samples. Choosing between profiling intact cells or isolated nuclei affects the biology measured and depends on aspects of the starting material. While intact cells capture both nuclear and cytoplasmic RNA, their quality is often compromised if they come from frozen or archived samples. There are similar issues if cells come from fibrous, dense, or enzyme-rich tissues. In these cases, researchers may want to work with nuclei instead, although nuclear RNA profiles are not identical to those from whole cells—they lack cytoplasmic RNA information, missing insight into mRNA regulation and turnover that occurs there.

If choosing to perform scRNA-seq on intact cells, researchers should start with a high-quality single-cell suspension with over 90% viable cells.² To obtain this starting material, cells must first be harvested and dissociated before capture and sequencing, and care should be taken to not alter the gene expression profile before library creation.

Harvesting cells from fresh tissue may produce more accurate results than using frozen samples, but scientists must move quickly to preserve their samples. For example, experts studying bladder cancer recommend isolating tissue samples from removed bladders while on ice 15 minutes after surgery, placing them in tissue preservation solution, and keeping them chilled when transporting to the laboratory within 30 minutes.³ For any sample type, it is best practice to rinse with chilled solutions, keep samples on ice, and centrifuge in cooled instruments.

After harvest, cells in blood or other liquid suspensions, such as peripheral blood mononuclear cells or cryopreserved cells, can move directly to the capture step, but other sample types need to be dissociated. Tissues require mechanical dissociation, which involves mincing the material followed by removing the extracellular matrix through enzymatic treatment. Next comes washing and filtering dead cells, aggregates, and debris. Enzymes, incubation times, washing, centrifugation conditions, and buffers should be optimized according to the sample, and researchers should take care to minimize RNA degradation during all steps by using RNase inhibitors and nuclease-free reagents.

“A common mistake is assuming that a protocol that works for one tissue will transfer directly to another. Over digestion, harsh mechanical disruption, long processing times, or inappropriate enzyme selection can reduce viability, alter cell state signatures, or selectively lose fragile cell types. Under-dissociation can leave aggregates and make the recovered population less representative of the original tissue,” notes Sinclair.

Capture method

After assessing their sample’s cell viability and concentration following dissociation, scientists move on to the capture step, which isolates and lyses cells and tags released transcripts with their cell of origin. While there are several capture techniques to choose from, some of the most popular are droplet, microwell, and plate-based methods.⁴

Central to many capture methods is molecular barcoding, where each cell is paired with a bead carrying millions of copies of a unique DNA tag, so that when the cell is lysed, every transcript captured from it gets stamped with that same barcode during reverse transcription. Many chemistries also add a second, shorter unique molecular identifier to each transcript, which later lets researchers distinguish original molecules from PCR duplicates. Because every transcript carries its cell’s barcode, thousands of cells can be pooled together for sequencing and sorted back out computationally afterward.

In droplet methods, microfluidics captures individual cells with barcoded beads and reagents inside nanoliter droplets. This technique is high throughput, but researchers have less control over the cell input. Microwell-based systems, where cells are applied to micro- or nano-well plates, are lower throughput than droplet, but they allow for visualization of captured cells to identify damaged cells or wells without cells. Plate-based methods are even lower throughput, capturing one cell per well, but they allow for high-depth, full-length transcript coverage.

Sequencing considerations

Many popular scRNA-seq methods tag and sequence the 5' or 3' transcript ends only. They profile many cells and detect numerous transcripts in comparison to full-length methods. However, because only the ends are sequenced, transcripts can only be identified and quantified; scientists lose information about internal transcript regions. Sequencing full-length transcripts generates data about isoforms and single nucleotide variants, although these techniques are typically higher in cost and generate large volumes of data on smaller numbers of cells.⁵ This is an important trade-off between transcript coverage and sensitivity for researchers to weigh.

A related but distinct trade-off is how many cells to profile versus how deeply to sequence each one. “More cells improve representation of heterogeneous samples and the ability to recover rare populations. Greater sequencing depth can improve detection of lower abundance transcripts and more subtle expression differences within each cell,” says Sinclair. “The right balance depends on the biological endpoint.” In practice, Sinclair recommends working backward from the biology. A researcher working on a cell atlas project focused on population structure may lean toward more cells, while a study probing subtle pathway shifts within one defined population may benefit from greater depth. The key is to estimate the abundance of the rarest population that needs to be detected, determine how many of those cells the analysis requires, and let that set the total cell count target.

Controls

As with any experiment, scRNA-seq requires careful planning of controls to separate technical effects from true biology. This helps the scientist determine if the workflow performed as they expected. “Depending on the study, these may include a consistent reference sample across runs, matched untreated or baseline samples, appropriate positive and negative controls, and balanced assignment of conditions across batches,” says Sinclair. “Separately, sample and data quality measures such as viability, recovery, RNA quality, ambient RNA, and doublet rates should be reviewed before biological differences are interpreted.”

In addition, researchers should ensure that they are working with biological replicates, where they run the same experiment on multiple independent samples, rather than just profiling many cells from the same sample. These replicates come from different donors or specimens and are important for estimating biological variability and determining whether observed differences are statistically meaningful.

Advice from the experts for first-timers

“Think big and don’t limit your project based on what you currently know about scRNA-seq cost structure. In the last few years, the price of both library prep and sequencing has dropped drastically, allowing scientists to do the experiments they envision and not limit themselves.” — Zohar Shipony, Director of Emerging Technologies at Ultima Genomics

“Start with the biological question rather than allowing the technical limitations of a platform to define the experiment. Define the comparison, the populations that need to be resolved, and the result that would meaningfully answer the question. Then work backward into sample preparation, replication, cell number, sequencing depth, and analysis. Pilot the most uncertain part of the experiment, especially with difficult tissues or limited samples. A small pilot can reveal problems with preparation, recovery, cell type representation, or study logistics before they affect an entire cohort.” — Aisling Sinclair, Senior Product Marketing Manager at Parse Biosciences

References

1. Wolfien M, et al. Single-cell RNA sequencing procedures and data analysis. In: Bioinformatics, 2021:19-35.

2. Sant P, et al. Approaches for single-cell RNA sequencing across tissues and cell types. Transcription. 2023;14(3-5):127-145.

3. Mao W, et al. Protocol for single-cell RNA sequencing and spatial transcriptomics of bladder Ewing sarcoma. STAR Protocols. 2025;6(1):103687.

4. Elshiekh D, et al. Single-cell sequencing in molecular diagnostics: Transformative yet untapped potential. Frontiers in Genetics. 2025;16:1621081.

5. Desta GM, Birhanu AG. Advancements in single-cell RNA sequencing and spatial transcriptomics: transforming biomedical research. Acta Biochimica Polonica. 2025;72:13922.